評論
打印
The CEO of the pharmaceutical company that makes the life-saving EpiPen strongly defended the product's huge price hike on Capitol Hill on Wednesday. Mylan's Heather Bresch testified under oath in front of the House Oversight and Government Reform Committee, where lawmakers piled on criticism about the injector's nearly-500 percent price increase.
周三，生產急救藥腎上腺素筆（EpiPen）的制藥公司首席執行官在美國國會為該產品的高價強烈辯護。邁蘭公司的希瑟·布萊什在眾議院監管和政府改革委員會面前宣誓作證，立法者對該注射筆近500%的價格上漲表達了不滿。
The hearing lasted well into the evening. Bresch said she wished Mylan had “better anticipated” the problems patients would face, as the company ratcheted up the cost of the device that stops life-threatening allergic reactions. CBS News reviewed documents the company turned over to lawmakers.
聽證會一直持續到晚上。布萊什稱她希望邁蘭公司“最好已經預測到”病人們即將面臨的問題，因為該公司逐漸提高了治療威脅生命的過敏反應的設備花費。哥倫比亞廣播公司查看了米蘭公司交給立法者的文件。
They show Mylan expects the EpiPen to generate $1.1 billion in net sales this year. It spends an estimated $85 million to market the device. Bresch claimed her own salary last year was $18m.
他們表明邁蘭公司希望腎上腺素注射筆今年的凈銷售額能達到11億美元。讓該設備上市大概要花費8500萬美元。布萊什稱她上個月的工資是1800萬美元。
譯文屬可可英語創，未經允許，不得轉載。
